adalimumab + Methotrexate
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Juvenile Idiopathic Arthritis
Conditions
Juvenile Idiopathic Arthritis, JIA
Trial Timeline
Jul 11, 2008 → Feb 1, 2024
NCT ID
NCT00783510About adalimumab + Methotrexate
adalimumab + Methotrexate is a pre-clinical stage product being developed by AbbVie for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00783510. Target conditions include Juvenile Idiopathic Arthritis, JIA.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02196701 | Phase 3 | Completed |
| NCT01185301 | Phase 3 | Completed |
| NCT01185288 | Approved | Completed |
| NCT01162421 | Approved | Completed |
| NCT00808509 | Approved | Completed |
| NCT00783510 | Pre-clinical | Completed |
Competing Products
20 competing products in Juvenile Idiopathic Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX-200 + Placebo | Polaryx Therapeutics | Phase 3 | 69 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Adalimumab | Eisai | Phase 3 | 77 |
| Abatacept | Ono Pharmaceutical | Phase 3 | 77 |
| Ixekizumab + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Tocilizumab | Eli Lilly | Phase 3 | 77 |
| Upadacitinib | AbbVie | Phase 1 | 33 |
| Upadacitinib + Tocilizumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Risankizumab | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| naproxen + esomeprazole | AstraZeneca | Phase 1 | 33 |
| Alendronate (Fosamax) | Merck | Pre-clinical | 23 |
| canakinumab | Novartis | Phase 3 | 77 |
| Secukinumab | Novartis | Phase 1 | 33 |
| ACZ885 150 mg (Canakinumab) | Novartis | Phase 3 | 77 |